167081-32-5

Basic information

• Product Name: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-oxo-, 1,1-diMethylethyl ester
• Synonyms: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-oxo-, 1,1-diMethylethyl ester;3-oxo-2-aza-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid tert-butyl ester;3-Oxo-2-azabicyclo[2.2.1]heptan-2-carboxylic acid tert-butyl ester;tert-butyl 3-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylate
• CAS NO: 167081-32-5
• Molecular Formula: C₁₁H₁₇NO₃
• Molecular Weight: 211.25758
• Mol File: 167081-32-5.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-oxo-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-oxo-, 1,1-diMethylethyl ester(167081-32-5)
• EPA Substance Registry System: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-oxo-, 1,1-diMethylethyl ester(167081-32-5)

Safety Data

• Hazardous Substances Data: 167081-32-5(Hazardous Substances Data)

Usage

General Description

The chemical "2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-oxo-, 1,1-diMethylethyl ester" is a compound with the molecular formula C11H17NO3. It is also known as N-Boc-3-pyrrolidone and is commonly used as a building block in the synthesis of pharmaceuticals and other organic compounds. It is a white crystalline solid with a melting point of 93-95 degrees Celsius and a boiling point of 330 degrees Celsius. This chemical is used as an intermediate in the production of various drugs and can be found in research laboratories and pharmaceutical manufacturing facilities.

Upstream product

• 1122-58-3 dmap 
• 24647-29-8 2-Azabicyclo[2.2.1]heptan-3-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 49805-30-3 2-azabicyclo[2.2.1.]hept-5-en-3-one 
• 134795-25-8 2-aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 
• 162427-15-8 3-oxo-2-aza-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid tert-butyl ester 

Downstream Products

• 167081-31-4 (cis-3-hydroxymethyl-cyclopentyl)-carbamic acid tert-butyl ester 
• 862700-28-5 tert-butyl (3-(aminomethyl)cyclopentyl)carbamate 
• 554451-12-6 (1S,3R)-3-tert-butoxycarbonylamino-cyclopentanecarboxylic acid methyl ester 
• 167081-31-4 (+/-)-(1SR,3RS)-3-N-BOC-aminocyclopentylmethanol 
• 167081-31-4 (3-Hydroxymethylcyclopentyl)carbamic acid t-butyl ester 

Relevant articles and documents

Decarboxylative Oxygenation via Photoredox Catalysis

The direct conversion of aliphatic carboxylic acids to their dehomologated carbonyl analogues has been accomplished through photocatalytic decarboxylative oxygenation. This transformation is applicable to an array of carboxylic acid motifs, producing ketones, aldehydes, and amides in excellent yields. Preliminary results demonstrate that this methodology is further amenable to aldehyde substrates via in situ oxidation to the corresponding acid and subsequent decarboxylative oxygenation. We have exploited this strategy for the sequential oxidative dehomologation of linear aliphatic chains.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR

The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.